Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (70) 70
oncology (64) 64
index medicus (59) 59
child (50) 50
female (48) 48
pediatrics (47) 47
adolescent (46) 46
male (45) 45
child, preschool (43) 43
infant (37) 37
children (34) 34
cancer (33) 33
chemotherapy (31) 31
hematology (30) 30
neuroblastoma (30) 30
article (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
health aspects (16) 16
infant, newborn (15) 15
patients (15) 15
retrospective studies (15) 15
acute myeloid leukemia (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
care and treatment (12) 12
leukemia (12) 12
mortality (12) 12
tumors (12) 12
acute myeloid-leukemia (11) 11
disease-free survival (11) 11
prognosis (11) 11
adult (10) 10
clinical trials (10) 10
follow-up studies (10) 10
leukemia, myeloid, acute - drug therapy (10) 10
therapy (10) 10
treatment outcome (10) 10
united-states (10) 10
analysis (9) 9
diagnosis (9) 9
high-risk neuroblastoma (9) 9
medical informatics (9) 9
neuroblastoma - therapy (9) 9
stem cells (9) 9
young adult (9) 9
cohort studies (8) 8
epidemiology (8) 8
n-myc (8) 8
neoplasms - drug therapy (8) 8
neuroblastoma - drug therapy (8) 8
neuroblastoma - genetics (8) 8
research (8) 8
risk (8) 8
risk factors (8) 8
transplantation (8) 8
camptothecin - analogs & derivatives (7) 7
databases, factual (7) 7
hematology, oncology and palliative medicine (7) 7
maximum tolerated dose (7) 7
neuroblastoma - pathology (7) 7
solid tumors (7) 7
united states (7) 7
usage (7) 7
abridged index medicus (6) 6
acute lymphoblastic-leukemia (6) 6
animals (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
camptothecin - administration & dosage (6) 6
expression (6) 6
hospitals (6) 6
medical research (6) 6
neuroblastoma - mortality (6) 6
neutropenia (6) 6
oncology-group (6) 6
original reports (6) 6
radiation-therapy (6) 6
relapse (6) 6
stem-cell transplantation (6) 6
survival (6) 6
antineoplastic agents - adverse effects (5) 5
benzoquinones (5) 5
childrens oncology group (5) 5
classification (5) 5
cohort (5) 5
dacarbazine - administration & dosage (5) 5
dacarbazine - analogs & derivatives (5) 5
dose-response relationship, drug (5) 5
hospitals, pediatric (5) 5
hospitals, pediatric - statistics & numerical data (5) 5
hsp90 heat-shock proteins - antagonists & inhibitors (5) 5
hsp90 heat-shock proteins - metabolism (5) 5
immunotherapy (5) 5
lactams, macrocyclic (5) 5
medical colleges (5) 5
molecular chaperone (5) 5
neoplasm recurrence, local - drug therapy (5) 5
neuroblastoma - diagnostic imaging (5) 5
pediatric (5) 5
pediatric-oncology-group (5) 5
pediatric-patients (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Mechanisms of neuroblastoma regression
by Brodeur, Garrett M and Bagatell, Rochelle
Nature Reviews Clinical Oncology, ISSN 1759-4774, 12/2014, Volume 11, Issue 12, pp. 704 - 713
Recent genomic and biological studies of neuroblastoma have shed light on the dramatic heterogeneity in the clinical behaviour of this disease, which spans... 
ONCOLOGY | MIGRATION INHIBITORY FACTOR | PHASE-I TRIAL | N-MYC AMPLIFICATION | MYOCLONUS-ATAXIA SYNDROME | NEUROTROPHIC FACTOR ACTIVATION | STAGE 4S NEUROBLASTOMA | HIGH-RISK NEUROBLASTOMA | CHILDRENS-CANCER-GROUP | OPSOCLONUS-MYOCLONUS | NEURAL CREST | Signal Transduction | Epigenesis, Genetic - genetics | Genomics | Humans | Neuroblastoma - genetics | Regression (Disease) | Care and treatment | Neuroblastoma | Research | Oncology, Experimental | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Neuroblastoma
by Maris, John M, MD and Hogarty, Michael D, MD and Bagatell, Rochelle, MD and Cohn, Susan L, Prof
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9579, pp. 2106 - 2120
Summary The clinical hallmark of neuroblastoma is heterogeneity, with the likelihood of cure varying widely according to age at diagnosis, extent of disease,... 
Internal Medicine | CENTRAL HYPOVENTILATION SYNDROME | MEDICINE, GENERAL & INTERNAL | PHASE-I TRIAL | PEDIATRIC-ONCOLOGY-GROUP | MYOCLONUS-ATAXIA SYNDROME | CHILDRENS CANCER GROUP | HIGH-RISK NEUROBLASTOMA | COMPARATIVE GENOMIC HYBRIDIZATION | ANGIOGENESIS INHIBITOR TNP-470 | MINIMAL RESIDUAL DISEASE | GROWTH-FACTOR EXPRESSION | Gene Expression Profiling - methods | Neuroblastoma - physiopathology | Neuroblastoma - therapy | Prognosis | Humans | Neuroblastoma - genetics | Proteins | Clinical trials | Mortality | Apoptosis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Tandem Transplant for High-Risk Neuroblastoma: Next Steps in the Era of Precision Medicine
by Bagatell, R and Irwin, MS
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 08/2019, Volume 322, Issue 8, pp. 729 - 731
The article discusses the findings of a study to evaluate whether tandem autologous transplant is effective in improving event-free survival (EFS) as compared... 
MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | THERAPY | DISEASE | OPEN-LABEL | HIGH-DOSE CHEMOTHERAPY | PROGNOSTIC-SIGNIFICANCE | INDUCTION | STAGE 4 NEUROBLASTOMA | CHILDREN | Care and treatment | Usage | Transplantation | Neuroblastoma | Risk factors | Stem cells | Risk groups | Precision medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Altered Hsp90 function in cancer: A unique therapeutic opportunity
by Rochelle Bagatell and Luke Whitesell
Molecular Cancer Therapeutics, ISSN 1535-7163, 08/2004, Volume 3, Issue 8, pp. 1021 - 1030
Molecular chaperones or so-called heat shock proteins serve as central integrators of protein homeostasis within cells. In performing this function, they guide... 
SIGNAL-TRANSDUCTION | MORPHOLOGICAL EVOLUTION | MOLECULAR CHAPERONE HSP90 | DIFFERENTIAL EXPRESSION | ONCOLOGY | TYROSINE KINASE | IN-VIVO | LEUKEMIA-CELLS | HUMAN BREAST-CANCER | ANTITUMOR-ACTIVITY | HEAT-SHOCK-PROTEIN | Neoplasms - metabolism | Cell Proliferation | Molecular Chaperones - metabolism | HSP90 Heat-Shock Proteins - physiology | Humans | Rifabutin - analogs & derivatives | Enzyme Inhibitors - pharmacology | Clinical Trials as Topic | Benzoquinones | Lactams, Macrocyclic | Rifabutin - pharmacology | Animals | HSP90 Heat-Shock Proteins - metabolism | Antineoplastic Agents - pharmacology | Cell Differentiation | Neoplasms - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
by Mody, Rajen, MD and Naranjo, Arlene, PhD and Van Ryn, Collin, MS and Yu, Alice L, Prof and London, Wendy B, PhD and Shulkin, Barry L, Prof and Parisi, Marguerite T, Prof and Servaes, Sabah-E-Noor, MD and Diccianni, Mitchell B, PhD and Sondel, Paul M, Prof and Bender, Julia G, MD and Maris, John M, Prof and Park, Julie R, Prof and Bagatell, Rochelle, Dr
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 946 - 957
Summary Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in... 
Hematology, Oncology and Palliative Medicine | Dacarbazine - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | N-Myc Proto-Oncogene Protein - genetics | Neoplasm Recurrence, Local - drug therapy | Infant | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Pain - chemically induced | Fever - chemically induced | Infection - chemically induced | Ganglioneuroblastoma - diagnostic imaging | Neoplasm Recurrence, Local - diagnostic imaging | Hypokalemia - chemically induced | Dacarbazine - analogs & derivatives | Camptothecin - administration & dosage | Ganglioneuroblastoma - drug therapy | Neutropenia - chemically induced | Child | Sirolimus - adverse effects | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Dacarbazine - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Sirolimus - analogs & derivatives | Ganglioneuroblastoma - genetics | Neuroblastoma - genetics | Anemia - chemically induced | Neuroblastoma - diagnostic imaging | Survival Rate | Thrombocytopenia - chemically induced | Disease-Free Survival | Retreatment | Sirolimus - administration & dosage | Gene Amplification | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Adolescent | Neoplasm Recurrence, Local - genetics | Hypoxia - chemically induced | Medical colleges | Stem cells | Neuroblastoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Refining megatherapy, improving outcome in neuroblastoma
by Bagatell, Rochelle and Grupp, Stephan A
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 423 - 424
Hematology, Oncology and Palliative Medicine | ONCOLOGY | HIGH-RISK NEUROBLASTOMA | ISOTRETINOIN | STAGE | CHEMOTHERAPY | TRANSPLANTATION | Disease-Free Survival | Infant | Neuroblastoma | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study
by Shanu Modi and Alison T. Stopeck and Michael S. Gordon and David Mendelson and David B. Solit and Rochelle Bagatell and Weining Ma and Jennifer Wheler and Neal Rosen and Larry Norton and Gillian F. Cropp and Robert G. Johnson and Alison L. Hannah and Clifford A. Hudis
Journal of Clinical Oncology, ISSN 0732-183X, 12/2007, Volume 25, Issue 34, pp. 5410 - 5417
Purpose This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination... 
HSP90 | HEAT-SHOCK-PROTEIN-90 | INHIBITION | THERAPY | SOLID TUMORS | 17-ALLYLAMINO | ONCOLOGY | 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN | 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN | 17-DEMETHOXYGELDANAMYCIN | DEGRADATION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Benzoquinones - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Breast Neoplasms - metabolism | Benzoquinones - pharmacokinetics | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Breast Neoplasms - enzymology | Aged, 80 and over | Adult | Female | Lactams, Macrocyclic - administration & dosage | Lactams, Macrocyclic - adverse effects | Receptor, ErbB-2 - biosynthesis | Antibodies, Monoclonal - pharmacokinetics | Breast Neoplasms - drug therapy | Drug Synergism | Lactams, Macrocyclic - pharmacokinetics | Antibodies, Monoclonal - administration & dosage | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Aged | Infusions, Intravenous | Benzoquinones - adverse effects | Trastuzumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Advances in neuroblastoma therapy
by MacFarland, Suzanne and Bagatell, Rochelle
Current opinion in pediatrics, ISSN 1040-8703, 02/2019, Volume 31, Issue 1, pp. 14 - 20
Purpose of review Our understanding of the biologic basis of neuroblastoma, the genetic heterogeneity of this malignancy and the role of host factors has... 
targeted therapy | NATURAL-KILLER-CELLS | risk classification | neuroblastoma | predisposition | OPEN-LABEL | CHEMOTHERAPY | RADIATION-THERAPY | CHILDREN | ANTI-GD2 MONOCLONAL-ANTIBODY | COPY-NUMBER | immunotherapy | PEDIATRICS | LOCAL-CONTROL | HIGH-RISK NEUROBLASTOMA | SEQUENCING REVEALS | Care and treatment | Forecasts and trends | Neuroblastoma | Risk factors | Methods | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials
by London, Wendy B and Bagatell, Rochelle and Weigel, Brenda J and Fox, Elizabeth and Guo, Dongjing and Van Ryn, Collin and Naranjo, Arlene and Park, Julie R
Cancer, ISSN 0008-543X, 12/2017, Volume 123, Issue 24, pp. 4914 - 4923
BACKGROUND Early‐phase trials in patients with recurrent neuroblastoma historically used an objective “response” of measureable disease (Response Evaluation... 
prognostic | historical standard | endpoints | phase 2 design | International Neuroblastoma Response Criteria (INRC) | Response Evaluation Criteria In Solid Tumors (RECIST) | SYSTEM | DIAGNOSIS | PROGNOSIS | RISK GROUP | RELAPSE | PATHOLOGY CLASSIFICATION | INTERNATIONAL CRITERIA | ONCOLOGY | STRATIFICATION | AGE | Follow-Up Studies | United States | Humans | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Infant | Male | Response Evaluation Criteria in Solid Tumors | Neuroblastoma - mortality | Neuroblastoma - therapy | Neoplasm Recurrence, Local - mortality | Cause of Death | Neoplasm Recurrence, Local - pathology | Female | Child | Neuroblastoma - pathology | Medical Oncology - methods | Risk Assessment | Neoplasm Recurrence, Local - therapy | Treatment Outcome | Combined Modality Therapy | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Usage | Oncology | Development and progression | Transplantation | Research | Neuroblastoma | Children | Health aspects | Hematopoietic stem cells | Therapy | Clinical trials | Stem cell transplantation | Standard error | Bone tumors | Design | Historical account | Bone marrow | Risk groups | Benchmarks | Patients | Survival | Hemopoiesis | Children & youth | Heterozygosity | Studies | Loss of heterozygosity | Stem cells | Bone | Solid tumors | Tumors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma
by Balis, Frank Milton and Busch, Christine Maria and Desai, Ami Vijay and Hibbitts, Emily and Naranjo, Arlene and Bagatell, Rochelle and Irwin, Meredith and Fox, Elizabeth
Pediatric Blood & Cancer, ISSN 1545-5009, 01/2020, Volume 67, Issue 1, p. n/a
Background GD2 is a ganglioside that is ubiquitously expressed in the plasma membrane of neuroblastoma and is shed into the circulation. Procedure GD2 was... 
neuroblastoma | biomarker | ganglioside | Biomarkers | Mass spectroscopy | Risk | Liquid chromatography | Diagnostic systems | Neuroblastoma | Children | Diagnosis | Mass spectrometry | Fatty acids | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
by Rochelle Bagatell and Wendy B. London and Lars M. Wagner and Stephan D. Voss and Clinton F. Stewart and John M. Maris and Cynthia Kretschmar and Susan L. Cohn
Journal of Clinical Oncology, ISSN 0732-183X, 01/2011, Volume 29, Issue 2, pp. 208 - 213
Purpose This phase II study was conducted to determine the response rate associated with use of irinotecan and temozolomide for children with... 
ORAL IRINOTECAN | TRIAL | PROTRACTED IRINOTECAN | XENOGRAFT MODELS | SOLID TUMORS | CPT-11 | ONCOLOGY | PEDIATRIC-PATIENTS | TOPOISOMERASE-I | HIGH-RISK NEUROBLASTOMA | EWING SARCOMA | Camptothecin - adverse effects | Dacarbazine - administration & dosage | Dacarbazine - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Adolescent | Dacarbazine - analogs & derivatives | Camptothecin - administration & dosage | Female | Child | Camptothecin - analogs & derivatives | Pedi10 | Original Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study
by Bagatell, Rochelle and Norris, Robin and Ingle, Ashish M and Ahern, Charlotte and Voss, Stephan and Fox, Elizabeth and Little, Anthony R and Weigel, Brenda J and Adamson, Peter C and Blaney, Susan
Pediatric Blood & Cancer, ISSN 1545-5009, 05/2014, Volume 61, Issue 5, pp. 833 - 839
Background mTOR inhibitors have activity in pediatric tumor models. A phase I trial of the mTOR inhibitor temsirolimus (TEM) with irinotecan (IRN) and... 
temsirolimus | phase 1 | solid tumors | Temsirolimus | Phase 1 | Solid tumors | MAMMALIAN TARGET | RAPAMYCIN | EVEROLIMUS | NEUROBLASTOMA | CANCER | RENAL-CELL CARCINOMA | MTOR | INHIBITION | ONCOLOGY | GROWTH | RHABDOMYOSARCOMA | PEDIATRICS | HEMATOLOGY | Dacarbazine - administration & dosage | Sirolimus - analogs & derivatives | Prognosis | Follow-Up Studies | Humans | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Remission Induction | Neoplasms - drug therapy | Young Adult | Sirolimus - administration & dosage | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Dacarbazine - analogs & derivatives | Adult | Camptothecin - administration & dosage | Female | Child | Camptothecin - analogs & derivatives | Antimitotic agents | Relapse | Corticosteroids | Sarcoma | Anemia | Analysis | Clinical trials | Product development | Antineoplastic agents | Diseases | Medical research | Medical treatment | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group
by Campbell, Kevin and Gastier‐Foster, Julie M and Mann, Meegan and Naranjo, Arlene H and Ryn, Collin and Bagatell, Rochelle and Matthay, Katherine K and London, Wendy B and Irwin, Meredith S and Shimada, Hiroyuki and Granger, M. Meaghan and Hogarty, Michael D and Park, Julie R and DuBois, Steven G
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 21, pp. 4224 - 4235
BACKGROUND High‐level MYCN amplification (MNA) is associated with poor outcome and unfavorable clinical and biological features in patients with neuroblastoma.... 
amplification | MYCN | neuroblastoma | segmental chromosomal aberration | prognosis | gain | ploidy | CHROMOSOME 1P | RISK GROUP PROJECT | CLASSIFICATION | ONCOLOGY | N-MYC | AMPLIFIED NEUROBLASTOMA | EXPRESSION | DELETIONS | STRATIFICATION | Humans | Neuroblastoma - genetics | Proportional Hazards Models | Child, Preschool | N-Myc Proto-Oncogene Protein - genetics | Ganglioneuroma - classification | Infant | Linear Models | Male | Gene Dosage | Neuroblastoma - mortality | Ganglioneuroma - genetics | Disease-Free Survival | Gene Amplification | Neuroblastoma - classification | Neuroblastoma - drug therapy | Ganglioneuroma - drug therapy | Female | Retrospective Studies | Neoplasm Staging | Oncology | Genetic aspects | Children | Research | Gene expression | Health aspects | Level (quantity) | Risk groups | Copy number | Health risks | Risk | Neuroblastoma | Survival | Patients | Rank tests | Amplification | Chemotherapy | Medical prognosis | Aberration | Tumors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights